Alzheimer'
Conditions
Interventions
[11C]PiB: approx. 370MBq (10mCi) 18F]PM-PBB3: approx. 185MBq (5mCi) PET scan, MRI scan Neuropsychological testing, and up to 10 ml of blood and CSF examinations
[11C]PiB: approx. 370MBq (10mC
Sponsors
National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Those who meet the diagnostic criteria for psychiatric and neurological disorders, such as Alzheimer's disease, where the accumulation of abnormal proteins, such as tau protein, has been suggested to be involved in the disorder.
Exclusion criteria
Exclusion criteria: (1) Patients with complications or those with a history of such complications and who are judged by the researcher or other physicians to be inappropriate for the study. (2) Patients with severe claustrophobia. (3) The person who is pregnant or may be pregnant and the person who is breastfeeding. (4) In the case of PET examination in this study, in consideration of exposure in nuclear medicine examination, the subject must be within 6 months from the time of participation in other studies involving radiation exposure. (5) Other persons who are judged by the physician to be unsuitable as research subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the association among tau/amyloid PET tracer, brain atrophy/function, fluid biomarkers and clinical information | — |
Countries
Japan
Contacts
Public ContactKenji Tagai
National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Scienc Department of Functional Brain Imaging Research
Outcome results
None listed